Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity

Judith Falloon, Stephen C. Piscitelli, S Vogel, Brian M. Sadler, Hiroaki Mitsuya, Mark F. Kavlick, Kazuhisa Yoshimura, M. Brooke Rogers, Stephen W. LaFon, Douglas J. Manion, H. Clifford Lane, Henry MasurClinical 2000 · DOI

Abstract

Patients with plasma viral RNA >50,000 copies/mL, despite a protease-inhibitor regimen, received abacavir, amprenavir, and efavirenz to assess efavirenz-amprenavir drug interactions and to evaluate safety and antiviral response. Patients first received amprenavir with abacavir and other nucleoside analogs. Amprenavir levels were measured before and after adding efavirenz. Patients then received a second protease inhibitor. There was evidence of genotypic and phenotypic resistance at study entry. No patient had study drugs discontinued because of toxicity. Efavirenz decreased the steady-state area under the curve, maximum plasma concentration, and minimum plasma concentration of amprenavir by 24%, 33%, and 43%, respectively. Three of 10 patients had >1.5 log10 viral response to abacavir and amprenavir. All 8 patients who added efavirenz had >0.5 log10 decline in viral load, and this response lasted >24 weeks for 3 of the patients. A combination regimen that included abacavir, amprenavir, and efavirenz was well tolerated and had sustained activity in some patients. Concomitant efavirenz therapy decreases amprenavir concentrations.
BibTeX
@inproceedings{falloon2000combination,
  author = {Judith Falloon and Stephen C. Piscitelli and S Vogel and Brian M. Sadler and Hiroaki Mitsuya and Mark F. Kavlick and Kazuhisa Yoshimura and M. Brooke Rogers and Stephen W. LaFon and Douglas J. Manion and H. Clifford Lane and Henry Masur},
  title = {{Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity}},
  booktitle = {Clinical},
  year = {2000},
  doi = {10.1086/313667},
}

Loading related content...

Figure